RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Adebayo Oyekan to Animals

This is a "connection" page, showing publications Adebayo Oyekan has written about Animals.
Connection Strength

0.915
  1. Edosuyi O, Adesuyi A, Choi M, Igbe I, Oyekan A. Malate reduced blood pressure and exerted differential effects on renal hemodynamics; role of the nitric oxide system and renal epithelial sodium channels (ENaC). Eur J Pharmacol. 2023 Jan 05; 938:175441.
    View in: PubMed
    Score: 0.071
  2. Edosuyi O, Choi M, Igbe I, Oyekan A. Fumarate exerted an antihypertensive effect and reduced kidney injury molecule (KIM)-1 expression in deoxycorticosterone acetate-salt hypertension. Clin Exp Hypertens. 2021 Aug 18; 43(6):555-564.
    View in: PubMed
    Score: 0.063
  3. Ozurumba E, Mathew O, Ranganna K, Choi M, Oyekan A. Regulation of hypoxia inducible factor/prolyl hydroxylase binding domain proteins 1 by PPARa and high salt diet. J Basic Clin Physiol Pharmacol. 2018 Mar 28; 29(2):165-173.
    View in: PubMed
    Score: 0.051
  4. Alshaman R, Truong L, Oyekan A. Role of mechanistic target of rapamycin (mTOR) in renal function and ischaemia-reperfusion induced kidney injury. Clin Exp Pharmacol Physiol. 2016 Nov; 43(11):1087-1096.
    View in: PubMed
    Score: 0.046
  5. Dallatu MK, Choi M, Oyekan AO. Inhibition of prolyl hydroxylase domain-containing protein on hypertension/renal injury induced by high salt diet and nitric oxide withdrawal. J Hypertens. 2013 Oct; 31(10):2043-9.
    View in: PubMed
    Score: 0.037
  6. Rizvi YQ, Mehta CS, Oyekan A. Interactions of PPAR-alpha and adenosine receptors in hypoxia-induced angiogenesis. Vascul Pharmacol. 2013 Nov-Dec; 59(5-6):144-51.
    View in: PubMed
    Score: 0.037
  7. Oyekan A. PPARs and their effects on the cardiovascular system. Clin Exp Hypertens. 2011; 33(5):287-93.
    View in: PubMed
    Score: 0.032
  8. Fidelis P, Wilson L, Thomas K, Villalobos M, Oyekan AO. Renal function and vasomotor activity in mice lacking the Cyp4a14 gene. Exp Biol Med (Maywood). 2010 Nov; 235(11):1365-74.
    View in: PubMed
    Score: 0.030
  9. Newaz M, Yousefipour Z, Oyekan A. Natriuretic and renoprotective effect of chronic oral neutral endopeptidase inhibition in acute renal failure. Ren Fail. 2010 Jan; 32(3):384-90.
    View in: PubMed
    Score: 0.029
  10. Yakubu MA, Nsaif RH, Oyekan AO. Regulation of cerebrovascular endothelial peroxisome proliferator activator receptor alpha expression and nitric oxide production by clofibrate. Bratisl Lek Listy. 2010; 111(5):258-64.
    View in: PubMed
    Score: 0.029
  11. Newaz M, Ranganna K, Truong LD, Oyekan A. Effect of peroxisome proliferator-activated receptor-alpha siRNA on hypertension and renal injury in the rat following nitric oxide withdrawal and high salt diet. J Hypertens. 2009 Nov; 27(11):2223-31.
    View in: PubMed
    Score: 0.029
  12. Banks T, Oyekan A. Peroxisome proliferator-activated receptor alpha activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat. J Hypertens. 2008 Mar; 26(3):468-77.
    View in: PubMed
    Score: 0.025
  13. Obih P, Oyekan AO. Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARalpha null mice. Blood Press. 2008; 17(1):55-63.
    View in: PubMed
    Score: 0.025
  14. Yakubu MA, Nsaif RH, Oyekan AO. peroxisome proliferator-activated receptor alpha activation-mediated regulation of endothelin-1 production via nitric oxide and protein kinase C signaling pathways in piglet cerebral microvascular endothelial cell culture. J Pharmacol Exp Ther. 2007 Feb; 320(2):774-81.
    View in: PubMed
    Score: 0.023
  15. Blanton A, Nsaif R, Hercule H, Oyekan A. Nitric oxide/cytochrome P450 interactions in cyclosporin A-induced effects in the rat. J Hypertens. 2006 Sep; 24(9):1865-72.
    View in: PubMed
    Score: 0.023
  16. Newaz MA, Yousefipour Z, Oyekan A. Oxidative stress-associated vascular aging is xanthine oxidase-dependent but not NAD(P)H oxidase-dependent. J Cardiovasc Pharmacol. 2006 Sep; 48(3):88-94.
    View in: PubMed
    Score: 0.023
  17. Williams J, Bogwu J, Oyekan A. The role of the RhoA/Rho-kinase signaling pathway in renal vascular reactivity in endothelial nitric oxide synthase null mice. J Hypertens. 2006 Jul; 24(7):1429-36.
    View in: PubMed
    Score: 0.023
  18. Newaz M, Yousefipour Z, Oyekan A. Role of PPAR-gamma on the pathogenesis and vascular changes in glycerol-induced acute renal failure. Pharmacol Res. 2006 Sep; 54(3):234-40.
    View in: PubMed
    Score: 0.022
  19. Newaz M, Blanton A, Fidelis P, Oyekan A. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)alpha-mediated cardiovascular effects. Mutat Res. 2005 Nov 11; 579(1-2):163-71.
    View in: PubMed
    Score: 0.021
  20. Oyekan AO. Differential effects of 20-hydroxyeicosatetraenoic acid on intrarenal blood flow in the rat. J Pharmacol Exp Ther. 2005 Jun; 313(3):1289-95.
    View in: PubMed
    Score: 0.021
  21. Yakubu MA, Sofola OA, Igbo I, Oyekan AO. Link between free radicals and protein kinase C in glucose-induced alteration of vascular dilation. Life Sci. 2004 Oct 29; 75(24):2921-32.
    View in: PubMed
    Score: 0.020
  22. Newaz MA, Ranganna K, Oyekan AO. Relationship between PPARalpha activation and NO on proximal tubular Na+ transport in the rat. BMC Pharmacol. 2004 Feb 06; 4:1.
    View in: PubMed
    Score: 0.019
  23. Sofola O, Yakubu M, Igbo I, Newaz M, Oyekan A. High salt diet modulates cAMP- and nitric oxide-mediated relaxation responses to isoproterenol in the rat aorta. Eur J Pharmacol. 2003 Aug 08; 474(2-3):241-7.
    View in: PubMed
    Score: 0.019
  24. Newaz MA, Yousefipour Z, Hercule H, Truong L, Oyekan A. Chronic endopeptidase inhibition in DOCA-salt hypertension: mechanism of cardiovascular protection. Clin Exp Hypertens. 2003 Aug; 25(6):335-47.
    View in: PubMed
    Score: 0.018
  25. Ogungbade GO, Akinsanmi LA, Jiang H, Oyekan AO. Role of epoxyeicosatrienoic acids in renal functional response to inhibition of NO production in the rat. Am J Physiol Renal Physiol. 2003 Nov; 285(5):F955-64.
    View in: PubMed
    Score: 0.018
  26. Hercule HC, Wang MH, Oyekan AO. Contribution of cytochrome P450 4A isoforms to renal functional response to inhibition of nitric oxide production in the rat. J Physiol. 2003 Sep 15; 551(Pt 3):971-9.
    View in: PubMed
    Score: 0.018
  27. Oyekan AO. Contributions of nitric oxide and prostanoids and their signaling pathways to the renal medullary vasodilator effect of U46619 (9-11-dideoxy-11 alpha,9a-epoxymethano-prostaglandin F(2a)) in the rat. J Pharmacol Exp Ther. 2003 Feb; 304(2):507-12.
    View in: PubMed
    Score: 0.018
  28. Hercule H, Oyekan A. Renal cytochrome p450 oxygenases and preglomerular vascular response to arachidonic acid and endothelin-1 following ischemia/reperfusion. J Pharmacol Exp Ther. 2002 Aug; 302(2):717-24.
    View in: PubMed
    Score: 0.017
  29. Newaz MA, Oyekan AO. Contribution of renal oxygenases to glycerol-induced acute renal failure in the rat. J Cardiovasc Pharmacol. 2002 Jun; 39(6):834-41.
    View in: PubMed
    Score: 0.017
  30. Escalante BA, McGiff JC, Oyekan AO. Role of cytochrome P-450 arachidonate metabolites in endothelin signaling in rat proximal tubule. Am J Physiol Renal Physiol. 2002 Jan; 282(1):F144-50.
    View in: PubMed
    Score: 0.017
  31. Newaz MA, Yousefipour Z, Oyekan A. Effects of pergolide on blood pressure and tissue injury in DOCA-salt hypertension. Blood Press. 2002; 11(2):110-5.
    View in: PubMed
    Score: 0.017
  32. Oyekan AO. Cytochrome p450-dependent metabolites of arachidonic acid and renal function in the rat. Clin Exp Pharmacol Physiol. 2000 Aug; 27(8):581-6.
    View in: PubMed
    Score: 0.015
  33. Yousefipour Z, Oyekan A, Newaz M. Interaction of oxidative stress, nitric oxide and peroxisome proliferator activated receptor gamma in acute renal failure. Pharmacol Ther. 2010 Mar; 125(3):436-45.
    View in: PubMed
    Score: 0.007
  34. Yousefipour Z, Oyekan A, Newaz M. Role of G protein-coupled receptor kinase-2 in peroxisome proliferator-activated receptor gamma-mediated modulation of blood pressure and renal vascular reactivity in SHR. Am J Nephrol. 2009; 30(3):201-8.
    View in: PubMed
    Score: 0.007
  35. Anozie O, Ross R, Oyekan AO, Yakubu MA. Differential modulation of bradykinin-induced relaxation of endothelin-1 and phenylephrine contractions of rat aorta by antioxidants. Acta Pharmacol Sin. 2007 Oct; 28(10):1566-72.
    View in: PubMed
    Score: 0.006
  36. Yousefipour Z, Hercule H, Truong L, Oyekan A, Newaz M. Ciglitazone, a peroxisome proliferator-activated receptor gamma inducer, ameliorates renal preglomerular production and activity of angiotensin II and thromboxane A2 in glycerol-induced acute renal failure. J Pharmacol Exp Ther. 2007 Aug; 322(2):461-8.
    View in: PubMed
    Score: 0.006
  37. Long DA, Newaz MA, Prabhakar SS, Price KL, Truong LD, Feng L, Mu W, Oyekan AO, Johnson RJ. Loss of nitric oxide and endothelial-derived hyperpolarizing factor-mediated responses in aging. Kidney Int. 2005 Nov; 68(5):2154-63.
    View in: PubMed
    Score: 0.005
  38. Sacerdoti D, Abraham NG, Oyekan AO, Yang L, Gatta A, McGiff JC. Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats. J Pharmacol Exp Ther. 2004 Feb; 308(2):636-43.
    View in: PubMed
    Score: 0.005
  39. Carroll MA, Ferreri NR, Escalante BA, Oyekan AO, McGiff JC. Cytochrome P450 arachidonic acid metabolites modulate renal tubular function. Adv Exp Med Biol. 2003; 525:67-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support